Boldenone – Kodiac biolabs

Plain-language summaryIntrigue 42 / 100

Boldenone is essentially testosterone with an added double bond between carbons 1 and 2. Originally approved in 1949 as a human drug at Ciba (Parenabol, withdrawn) and later developed for veterinary use as Equipoise, the name still associated with it. The 1,2 double bond makes the molecule a poorer substrate for aromatase, so it converts to estrogen at roughly half the rate of testosterone at equivalent doses, the main practical feature distinguishing it. The undecylenate ester gives the injectable formulation a long half-life around 14 days. Schedule III in the US under the AAS Control Act despite never having current human medical approval. Reference low-aromatizing testosterone analog in steroid pharmacology research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

24/100

Old veterinary AAS with narrow reference-probe utility and stagnant research trajectory

Boldenone is a 75-year-old compound. That’s the core of the story here. Ciba introduced it in 1949 as Parenabol for human use, pulled it, and it found its permanent home as Equipoise in veterinary practice. The research conversation around it has been essentially stagnant for decades; theres no active clinical development program, no IND, no therapeutic application on the horizon. For a library built around the frontier, boldenone is not there.

The mechanism is straightforward: androgen receptor agonism with the 1,2 double bond reducing aromatase substrate quality to roughly half that of testosterone. That’s the single pharmacological hook distinguishing boldenone from plain testosterone, and while it’s a real and measurable difference, it’s not a novel mechanism. It’s a structural variation on one of the most thoroughly studied receptor systems in endocrinology. Single-receptor agonism in a class that has dozens of characterized analogs doesn’t score high on mechanism promise, and boldenone doesn’t earn any points for mechanism elegance beyond that one structural tweak.

Where boldenone has some legitimate research value is as a reference compound. If you’re running in vitro or in vivo androgen biology work and you want to separate androgenic effects from estrogenic confounds without layering in an aromatase inhibitor, boldenone offers a cleaner experimental model. The erythropoietic effects have been studied, and the compound has shown up as a comparator in androgen receptor binding assays. That’s real bench utility, if narrow. We think the reference-probe angle is the only serious argument for keeping it in a research inventory.

The evidence base is a genuine problem. Most of what exists is pharmacokinetic characterization covering ester hydrolysis rates and detection windows for anti-doping work, plus veterinary pharmacology. Human clinical data is essentially observational, drawn from illicit use contexts rather than controlled trials. Replication across independent research groups for any specific effect claim is limited. Dont have the multi-lab, methodologically sound preclinical base you’d want before calling something a serious target.

Honestly, the main reason boldenone appears in a library like this is category completeness and its historical role as a reference AAS. For an investigator studying reduced-aromatization androgen biology, there are more accessible and better-characterized options: testosterone plus a well-characterized aromatase inhibitor gives more experimental control, and nandrolone carries actual clinical literature. We’d deprioritize boldenone for almost any active research program. The narrow reference-probe case keeps it off the floor, but old mechanism, thin controlled evidence, Schedule III friction, and a stagnant pipeline put it well down the priority list.

Novelty: 18
Mechanism promise: 20
In-category differentiation: 25
Evidence quality: 22
Translational signal: 28
Research bench value: 38

Rationale Boldenone scores low across novelty and mechanism because it’s a 75-year-old AR agonist variant with no active clinical program and a saturated-class mechanism; bench value is slightly elevated for its narrow use as a low-aromatizing reference probe, but the combination of thin controlled evidence and stagnant literature keeps the overall well below the Schedule III cap of 75.

Testosterone analog (1-dehydro testosterone)

A 1-dehydro testosterone analog; an injectable AAS originally developed for veterinary use, widely diverted to human non-medical use.

Abstract

Boldenone (17-beta-hydroxyandrosta-1,4-dien-3-one; CAS 846-48-0; molecular formula C19H26O2; molecular weight 286.41) is a 1-dehydro testosterone analog originally developed at Ciba and approved by the FDA in 1949 (Parenabol, withdrawn) and subsequently developed for veterinary use as Equipoise (the brand most associated with the compound). The 1,2 double bond reduces aromatase substrate quality, producing approximately 50 percent the estrogen conversion of testosterone at equivalent doses; this is the principal pharmacological feature distinguishing boldenone from testosterone. The undecylenate ester (Equipoise) provides a long half-life (approximately 14 days) for veterinary or non-medical injectable use. Schedule III in the US (covered by the AAS Control Act despite no human medical approval). Plasma half-life of native boldenone is short; ester formulations release over weeks. Used as a reference low-aromatizing testosterone analog in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-391Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.